RxDoctor Payments Data

Brad Stair, MD

Interventional Cardiology · New Haven, CTNPI 1275775488

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,988 of the $7,289 with a category attached, or 82.1%. 17 manufacturers reported payments, led by Abbott at 30.3% of the total. Reporting peaked in 2019 at $2,811 and has fallen 72.0% since, to $787 in 2025.

$7,289in general payments, 2019–2025

Across 121 payments — averaging $60.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$1K
  • Edwards Lifesciences$1K
  • Medtronic$746
  • Abiomed$348
  • W. L. Gore & Associates, Inc.$304
  • plus $883 from 11 others

What the payments were for

  • Travel & lodging$1,30118%
  • Food & beverage$5,98882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,289 in reported general payments places this provider in the 55th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$140,387
Medicare patients
878
Services billed
2,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$506,834
EliquisApixaban254$276,176
EntrestoSacubitril/Valsartan82$119,393
JardianceEmpagliflozin91$91,851
BrilintaTicagrelor78$76,883
Repatha SureclickEvolocumab78$70,673
XareltoRivaroxaban55$52,848
Praluent PenAlirocumab40$34,759
VascepaIcosapent Ethyl14$7,533
Metoprolol Succinate648$7,135
Atorvastatin Calcium527$5,079
Losartan Potassium247$2,672
Carvedilol201$1,955
ClopidogrelClopidogrel Bisulfate194$1,839
Torsemide120$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$12$52,84855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 73 interventional cardiology providers in Connecticut.

Other interventional cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →